Viking Therapeutics Inc., a biopharmaceutical company in its clinical-stage, is committed to developing innovative therapies for metabolic and endocrine disorders. The company's premier drug candidate, VK2809, is a selective agonist of the thyroid hormone receptor beta (TRß), and is currently undergoing Phase IIb clinical trials to treat biopsy-affirmed non-alcoholic steatohepatitis, as well as NAFLD. Viking Therapeutics is also developing VK5211 - a non-steroidal selective androgen receptor modulator that is orally available and is in its Phase II clinical trials. The drug is intended for patients recovering from non-elective hip fracture surgery. VK0612, another orally available drug candidate for type 2 diabetes, is Phase IIb-ready. The company is also conducting Phase 1 SAD/MAD clinical trials for VK2735, a novel dual agonist of the glucagon-like peptide, and VK0214, an orally-available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. Viking Therapeutics Inc. was founded in 2012 and is headquartered in San Diego, California.
Viking Therapeutics's ticker is VKTX
The company's shares trade on the NASDAQ stock exchange
They are based in San Diego, California
There are 11-50 employees working at Viking Therapeutics
It is vikingtherapeutics.com
Viking Therapeutics is in the Healthcare sector
Viking Therapeutics is in the Biotechnology industry
The following five companies are Viking Therapeutics's industry peers: